TY - JOUR
T1 - Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation
AU - de Koning, Coco
AU - Tao, Weiyang
AU - Lacna, Amelia
AU - van Veghel, Karin
AU - Horwitz, Mitchell E.
AU - Sanz, Guillermo
AU - Jagasia, Madan H.
AU - Wagner, John E.
AU - Stiff, Patrick J.
AU - Hanna, Rabi
AU - Cilloni, Daniela
AU - Valcárcel, David
AU - Peled, Tony
AU - Galamidi Cohen, Einat
AU - Goshen, Uri
AU - Pandit, Aridaman
AU - Lindemans, Caroline A.
AU - Jan Boelens, Jaap
AU - Nierkens, Stefan
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/11
Y1 - 2021/11
N2 - Omidubicel (nicotinamide-expanded cord blood) is a potential alternative source for allogeneic hematopoietic cell transplantation (HCT) when an HLA-identical donor is lacking. A phase I/II trial with standalone omidubicel HCT showed rapid and robust neutrophil and platelet engraftment. In this study, we evaluated the immune reconstitution (IR) of patients receiving omidubicel grafts during the first 6 months post-transplant, as IR is critical for favorable outcomes of the procedure. Data was collected from the omidubicel phase I-II international, multicenter trial. The primary endpoint was the probability of achieving adequate CD4+ T-cell IR (CD4IR: > 50 × 106/L within 100 days). Secondary endpoints were the recovery of T-cells, natural killer (NK)-cells, B-cells, dendritic cells (DC), and monocytes as determined with multicolor flow cytometry. LOESS-regression curves and cumulative incidence plots were used for data description. Thirty-six omidubicel recipients (median 44; 13–63 years) were included, and IR data was available from 28 recipients. Of these patients, 90% achieved adequate CD4IR. Overall, IR was complete and consisted of T-cell, monocyte, DC, and notably fast NK- and B-cell reconstitution, compared to conventional grafts. Our data show that transplantation of adolescent and adult patients with omidubicel results in full and broad IR, which is comparable with IR after HCT with conventional graft sources.
AB - Omidubicel (nicotinamide-expanded cord blood) is a potential alternative source for allogeneic hematopoietic cell transplantation (HCT) when an HLA-identical donor is lacking. A phase I/II trial with standalone omidubicel HCT showed rapid and robust neutrophil and platelet engraftment. In this study, we evaluated the immune reconstitution (IR) of patients receiving omidubicel grafts during the first 6 months post-transplant, as IR is critical for favorable outcomes of the procedure. Data was collected from the omidubicel phase I-II international, multicenter trial. The primary endpoint was the probability of achieving adequate CD4+ T-cell IR (CD4IR: > 50 × 106/L within 100 days). Secondary endpoints were the recovery of T-cells, natural killer (NK)-cells, B-cells, dendritic cells (DC), and monocytes as determined with multicolor flow cytometry. LOESS-regression curves and cumulative incidence plots were used for data description. Thirty-six omidubicel recipients (median 44; 13–63 years) were included, and IR data was available from 28 recipients. Of these patients, 90% achieved adequate CD4IR. Overall, IR was complete and consisted of T-cell, monocyte, DC, and notably fast NK- and B-cell reconstitution, compared to conventional grafts. Our data show that transplantation of adolescent and adult patients with omidubicel results in full and broad IR, which is comparable with IR after HCT with conventional graft sources.
UR - http://www.scopus.com/inward/record.url?scp=85111689320&partnerID=8YFLogxK
U2 - 10.1038/s41409-021-01417-4
DO - 10.1038/s41409-021-01417-4
M3 - Article
C2 - 34312498
AN - SCOPUS:85111689320
SN - 0268-3369
VL - 56
SP - 2826
EP - 2833
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 11
ER -